
June 2 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O:
REGENERON EXPANDS CLINICAL-STAGE OBESITY PORTFOLIO WITH STRATEGIC IN-LICENSING OF NOVEL DUAL GLP-1/GIP RECEPTOR AGONIST
REGENERON PHARMACEUTICALS INC - TO PAY $80 MILLION UPFRONT TO HANSOH
REGENERON PHARMACEUTICALS INC: POTENTIAL ADDITIONAL PAYMENTS OF UP TO $1.93 BILLION UNDER DEAL